ROCKVILLE, Md., Feb. 4,
2020 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American:
SYN), a diversified clinical-stage company leveraging the
microbiome to develop therapeutics designed to prevent and treat
gastrointestinal (GI) diseases in areas of high unmet need,
announced today that Steven A.
Shallcross, Chief Executive and Financial Officer, is
scheduled to present at the BIO CEO & Investor Conference on
Monday, February 10, 2020, at
11:00 a.m. (ET) at the New York
Marriott Marquis (Wilder room).
A live webcast of Synthetic Biologics' presentation may be
accessed by logging onto the internet at
http://www.veracast.com/webcasts/bio/ceoinvestor2020/17107426667.cfm.
A replay will be archived and accessible for 90 days at the same
website and at www.syntheticbiologics.com.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE American: SYN) is a
clinical-stage company developing therapeutics that preserve the
microbiome to protect and restore the health of patients. The
Company's lead candidates are: (1) SYN-004 (ribaxamase) which is
designed to degrade certain commonly used intravenous (IV)
beta-lactam antibiotics within the gastrointestinal (GI) tract to
prevent microbiome damage, C. difficile infection (CDI),
overgrowth of pathogenic organisms, the emergence of antimicrobial
resistance (AMR) and acute graft-versus-host-disease (aGVHD) in
allogeneic hematopoietic cell transplant (HCT) recipients, and (2)
SYN-010, which is intended to reduce the impact of
methane-producing organisms in the gut microbiome to treat an
underlying cause of irritable bowel syndrome with constipation
(IBS-C). The Company is also advancing SYN-020, an oral formulation
of the enzyme intestinal alkaline phosphatase (IAP) to treat both
local GI and systemic diseases, and has completed proof-of-concept
studies with monoclonal antibody therapies for the prevention and
treatment of pertussis. For more information, please visit
Synthetic Biologics' website at
www.syntheticbiologics.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/synthetic-biologics-to-present-at-the-2020-bio-ceo--investor-conference-300997898.html
SOURCE Synthetic Biologics, Inc.